HEPA News and Press, Hepion Pharmaceuticals Inc. From 11/26/19

Gainers: ChemoCentryx (NASDAQ: CCXI )  +261% . More news on: ChemoCentryx, Inc., Akerna Corp., Proteostasis Therapeutics, Inc., Stocks on the move, Read more ...

The current bull market began, in my opinion, in 2009 and should last into the 2030s. Coming out of a bear market, investor focus is initially on high quality companies whose stocks are attractively priced and, in most cases, dividend-protected. Over time, investors migrate down the market cap...

Gainers:  Wah Fu Education Group (NASDAQ: WAFU ) +203% . More news on: Wah Fu Education Group Limited, Hepion Pharmaceuticals, Inc., Stage Stores, Inc., Stocks on the move, Read more ...

Hepion Pharmaceuticals (NASDAQ: HEPA ) +57.4% pre-market after saying its CRV431 anti-fibrotic agent prevented the development of liver cirrhosis in a highly aggressive, pre-clinical model of liver disease. More news on: Hepion Pharmaceuticals, Inc., Healthcare stocks news, Stocks on t...

EDISON, NJ / ACCESSWIRE / November 20, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that CRV431, an anti...

This article was selected to be shared with PRO+ Short Ideas subscribers - find out more here . Enochian Biosciences ( ENOB ) is a biotech company with a pre-clinical pipeline focused on the treatment and cure of HIV. Enochian has a troubled past, with a lot of management shake-ups and ...

EDISON, NJ / ACCESSWIRE / November 7, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced that it will present ...

CRV431 has Potently Reduced Fibrosis in all Experimental Models Tested To Date EDISON, NJ / ACCESSWIRE / November 7, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease aris...

Hepion's CSO, Dr. Daren Ure, to Highlight CRV431 as a Novel Drug Candidate for Liver Fibrosis EDISON, NJ / ACCESSWIRE / October 23, 2019 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of live...

Point Roberts, WA and Delta, BC - October 18, 2019 (Investorideas.com Newswire) a global news source and leading investor resource announces its weekly roundup of stocks added to its global stock directories in cannabis, biotech, eSport, defense and mining. The newest cannabis, defense and m...